- Therapeutic Antibodies & Biosimilar ELISA Kits
- Anti-Omalizumab (Xolair®) ADA Qualitative ELISA Kit
Anti-Omalizumab (Xolair®) ADA Qualitative ELISA Kit
Enzyme immunoassay for the qualitative determination (screening) of antibodies to Omalizumab (Xolair®) in serum and plasmaThe ELISA Genie Antibody to omalizumab (Xolair®) Enzyme-Linked-ImmunoSorbent Assay (ELISA) Kit is intended for the qualitative determination of antibodies to omalizumab (Xolair®) in serum and plasma. It is for professional use only.
|Required Volume (μl)||10|
|Total Time (min)||140|
|Sample Type||Serum, Plasma|
|Number of Assays||96|
|Detection Limit (ng/mL)||plus/minus|
|Spike Recovery (%)||-|
|Shelf Life (year)||1|
About Anti-Omalizumab (Xolair®) ADA Qualitative
A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. Most likely removed by opsonization via the reticuloendothelial system. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile. Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.
Anti-Omalizumab (Xolair®) ADA Qualitative ELISA Kit test principle
The Elisa Genie Antibody to omalizumab (Xolair®) ELISA is a sandwich assay for the determination of antibodies against omalizumab in serum and plasma samples. During the first incubation period, antibodies to omalizumab (AT0) in patient serum/ plasma samples are captured by the drug omalizumab (Xolair®) coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled specific conjugate is added to each well and then incubated. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of ATO in sample.
Xolair® is a trademark of Novartis AG.